Having trouble accessing articles? Reset your cache.

TMC1 gene editing therapy for dominant progressive hearing loss

DISEASE CATEGORY: Otologic

INDICATION: Hearing loss

A CRISPR-Cas9-based gene editing therapy targeting TMC1 could prevent DFNA36, a

Read the full 151 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE